Analyst upgrades, downgrades and initiations: AA, GLW, HAL, NKE, SLM ...

More

Analyst Upgrades

  • Oppenheimer upgraded Genoptix (NASDAQ: GXDX) to Outperform from Perform and raised its target to $44 from $33 based on analysis of oncology testing reimbursement that indicates average revenue per case is within industry norms.
  • Deutsche Bank upgraded Legg Mason (NYSE: LM) to Hold from Sell citing reports that an activist investor, Nelson Peltz, has increased its stake in the company. The firm said fundamentals remain weak but the news will likely push shares higher.
  • Suntrust upgraded VCA Antech (NASDAQ: WOOF) to Buy from Neutral citing reduced headwinds and favorable risk/reward. The firm has a $30 target on shares.
  • SLM Corp. (NYSE: SLM) was upgraded to Overweight from Neutral at JPMorgan.
  • Diamond Offshore (NYSE: DO) and FMC Technologies (NYSE: FMC) were upgraded to Neutral from Sell at Goldman.

Analyst Downgrades

  • Jefferies downgraded Edison International (NYSE: EIX) to Hold from Buy based on valuation.
  • Canaccord downgraded First Solar (NASDAQ: FSLR) to Hold from Buy and kept a $180 target on the stock. The firm said management laid out ambitious targets at yesterday's analyst day but provided little visibility into further positive catalysts.
  • Susquehanna downgraded Nike (NYSE: NKE) to Neutral from Positive following the company's weak guidance.
  • American Reprographics (NYSE: ARP) was downgraded to Neutral from Outperform at Credit Suisse.
  • Halliburton (NYSE: HAL) was downgraded to Neutral from Conviction Buy at Goldman.
  • Babcock & Brown (NYSE: FLY) was cut to Hold from Buy at Argus.

Analyst Initiations

  • Citigroup is positive on Alcoa's (NYSE: AA) valuation and expects shares to benefit from a manufacturing and auto recovery. Shares were started with a Buy rating and $14 target.
  • Morgan Keegan is positive on Corning's (NYSE: GLW) restructuring initiatives, improved operating leverage, and robust demand. The firm initiated shares with an Outperform rating.
  • Roth Capital initiated Santarus (NASDAQ: SNTS) with a Buy rating and $6 target believes the stock is undervalued. The firm said its Zegerid Rx franchise is worth $3.50/share alone, that the OTC Zegerid is worth another $1/share, and that the GI pipeline may provide $1/share upside.
  • Watsco (NYSE: WSO) was started at JPMorgan with an Overweight rating and $56 target.
  • CommScope (NYSE: CTV) was initiated with a Buy rating and $32 target at Piper Jaffray.
  • Teekay LNG (NYSE: TGP) was initiated with an Equal Weight rating and $21 target at Morgan Stanley.
Symbol Lookup
IndexesChangePrice
DJIA+150.2510,058.64
NASDAQ+24.822,150.87
S&P 500+13.781,070.52

Last updated: February 09, 2010: 04:27 PM

Hot Stocks

DailyFinance Headlines

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines